Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2025-12-24 @ 9:14 PM
NCT ID:
NCT00730704
Eligibility Criteria:
Inclusion Criteria:
* Age 18-26 years.
* Patients hospitalized during the postpartum period after a normal spontaneous vaginal delivery, assisted vaginal delivery or Cesarean section.
* Patients who delivered a singleton fetus or multiple gestations are eligible for participation.
* Patients may have delivered at gestational ages 32-44 weeks.
* Patients must have signed informed consent.
* Patients must meet pre-entry criteria.
* Patients who are breast feeding are eligible for participation.
* Patients must have an obstetrician whom they have seen for obstetric care and plan to follow-up with in the postpartum period.
Exclusion Criteria:
* Age \< 18 or \> 26 years.
* Patients with hemophilia, other bleeding disorders or thrombocytopenia (platelets \< 100,000/ul).
* Patients receiving active anticoagulant therapy with warfarin, heparin or low molecular weight heparin.
* Pregnancy or planning pregnancy within the next 6 months.
* Ongoing bacteremia, endomyometritis or other serious febrile illness.
* Hypersensitivity to yeast, aluminum or other vaccine components.
* Prior vaccination with a prophylactic HPV vaccine (single or multiple doses).
* Patients who delivered a non-viable infant or an infant with severe congenital malformations.
* Patients who do not plan on following up postpartum with their local obstetrician or maternal fetal medicine specialist.
* Patients who are unwilling to receive subsequent doses of the HPV vaccine.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
26 Years
Study:
NCT00730704
Study Brief:
Protocol Section:
NCT00730704